PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NanoBio® Corporation announced today that data from recent animal studies of its NanoStat®-based intranasal respiratory syncytial virus (RSV) vaccine have been published in PLoS One, an international peer-reviewed online publication. The studies were conducted at the University of Michigan Medical School and Seattle Children's Research Institute, and demonstrate that NanoBio's RSV vaccine induces robust protective immunity in mice without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail.

RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop pulmonary disease and/or asthma from RSV that persists throughout adult life making them susceptible to re-infection. Currently, there are no approved vaccines for RSV.

Ali I. Fattom, Ph.D., Senior Vice President of Vaccine Research and Development at NanoBio, stated, "In these studies, we observed the NanoStat-based RSV vaccine to induce robust immunity while decreasing mucus production and increasing viral clearance without Th2-mediated immune potentiation. These attributes have not been seen with prior vaccine candidates, and indicate significant potential for the development of the first safe and effective RSV vaccine."

Dr. Fattom added, "Given the promising results from these studies, we are now on an aggressive development timeline for RSV. Our early research in other animal species mirrors what we have seen in mice. We have therefore recently procured a novel GMP antigen source for RSV, which will enable future testing of the NanoStat-based vaccine in a Phase 1 human study."

Source: NanoBio Corporation